Public Profile

Emergent BioSolutions

Emergent BioSolutions Inc., a leading biopharmaceutical company headquartered in the United States, specialises in developing and manufacturing vaccines and therapeutics for public health threats. Founded in 1998, the company has achieved significant milestones, including the acquisition of key assets that bolster its position in the biodefence and infectious disease sectors. With a strong operational presence across North America and Europe, Emergent BioSolutions focuses on core products such as vaccines for anthrax and smallpox, as well as treatments for opioid overdose. What sets the company apart is its commitment to addressing urgent health needs through innovative solutions and strategic partnerships. Recognised for its expertise in biodefence, Emergent BioSolutions continues to play a pivotal role in enhancing global health security.

DitchCarbon Score

How does Emergent BioSolutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

33

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

24

Industry Benchmark

Emergent BioSolutions's score of 33 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.

91%

Let us know if this data was useful to you

Emergent BioSolutions's reported carbon emissions

In 2023, Emergent BioSolutions reported total carbon emissions of approximately 35,292,000 kg CO2e, comprising 16,856,000 kg CO2e from Scope 1 emissions and 18,436,000 kg CO2e from Scope 2 emissions. This represents a decrease from 2022, when the company emitted about 40,434,000 kg CO2e, with Scope 1 emissions at 19,334,000 kg CO2e and Scope 2 emissions at 21,099,000 kg CO2e. Emergent BioSolutions has not disclosed any specific reduction targets or initiatives related to carbon emissions. The company has reported emissions intensity metrics, indicating approximately 13,900 kg CO2e per full-time equivalent employee in 2023, down from about 13,600 kg CO2e per employee in 2022. While the company has not set formal climate pledges or science-based targets, it continues to monitor and report its emissions, reflecting a commitment to transparency in its environmental impact.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
19,334,000
00,000,000
Scope 2
21,099,000
00,000,000
Scope 3
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Emergent BioSolutions's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Emergent BioSolutions is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Emergent BioSolutions is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Shantha Biotechnics Pvt. Ltd.

IN
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Grifols

ES
Medical, precision and optical instruments, watches and clocks (33)
Updated 1 day ago

Lonza

CH
Furniture; other manufactured goods n.e.c. (36)
Updated 3 days ago

Opiant Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sanofi

FR
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Glaxosmithkline

GB
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers